Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
195
-
Total 13F shares, excl. options
-
63.1M
-
Shares change
-
-69.7K
-
Total reported value, excl. options
-
$5.19B
-
Value change
-
-$1.95M
-
Put/Call ratio
-
0.49
-
Number of buys
-
107
-
Number of sells
-
-84
-
Price
-
$82.19
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q3 2020
230 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q3 2020.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 195 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 63.1M shares
of 96M outstanding shares and own 65.73% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (8.35M shares), Capital Research Global Investors (6.78M shares), Capital International Investors (6.2M shares), VANGUARD GROUP INC (5.36M shares), BlackRock Inc. (4.81M shares), FEDERATED HERMES, INC. (4.09M shares), Capital World Investors (3.24M shares), ALKEON CAPITAL MANAGEMENT LLC (1.88M shares), STATE STREET CORP (1.82M shares), and Clearbridge Investments, LLC (1.78M shares).
This table shows the top 195 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.